SCHEMBL691586

SCHEMBL691586

C#Cc1cccc(-c2nc(N)c(-c3cccc(C#C)c3)c(N)n2)c1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 11/20 0.42
ADORA1 P30542 9/20 0.42
ADORA3 P0DMS8 2/20 0.42
ABCG2 Q9UNQ0 1/20 0.41
CA12 O43570 1/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA9 Q16790 1/20 0.38
CA14 Q9ULX7 1/20 0.38
CLK4 Q9HAZ1 1/20 0.38
RAB9A P51151 1/20 0.38
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
HPGD P15428 1/20 0.37
KMT2A Q03164 1/20 0.37
HRH4 Q9H3N8 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27819271 0.83 ADORA2A (0.46) ADORA2AADORA1ADORA3ABCG2CA12
SCHEMBL15522138 0.80 ADORA2A (0.47) ADORA2AADORA1CLK4
SCHEMBL2253014 0.78 ABCG2 (0.49) ADORA2AADORA1ADORA3ABCG2CLK4
SCHEMBL4077942 0.78 ABCG2 (0.46) ADORA2AADORA1ADORA3ABCG2KDM4E
SCHEMBL7662098 0.76 IDO1 (0.42) ADORA2AADORA1ABCG2CLK4MEN1
Hydrochloric Acid SCHEMBL7019753 0.76 ABCG2 (0.39) ADORA2AADORA1ADORA3ABCG2
SCHEMBL8653512 0.76 ADORA2A (0.40) ADORA2AADORA1ADORA3ABCG2CLK4
SCHEMBL869532 0.76 ABCG2 (0.42) ADORA2AADORA1ADORA3ABCG2CLK4
SCHEMBL642249 0.75 ADORA2A (0.46) ADORA2AADORA1ABCG2CLK4KDM4E
Hydrochloric Acid SCHEMBL7652459 0.75 IDO1 (0.41) ADORA2AADORA1ABCG2CLK4MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105367503-A HETEROARYL COMPOUNDS AND USES THEREOF AVILA THERAPEUTICS INC 2016-03-02 CN disclosed
CN-101902911-B Heteroaryl compounds and uses thereof AVILA THERAPEUTICS, INC. (US) 2015-12-16 CN disclosed
EP-2421538-A1 HETEROARYL COMPOUNDS AND USES THEREOF Avila Therapeutics, Inc. (US) 2012-02-29 EP disclosed
US-20110230494-A1 HETEROARYL COMPOUNDS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2011-09-22 US disclosed
US-20110224432-A1 HETEROARYL COMPOUNDS AND USES THEREOF AVILA THERAPEUTICS, INC. (US) 2011-09-15 US disclosed
US-7989465-B2 4,6-disubstituted pyrimidines useful as kinase inhibitors AVILA THERAPEUTICS, INC. (US) 2011-08-02 US disclosed
US-7982036-B2 4,6-disubstitued pyrimidines useful as kinase inhibitors AVILA THERAPEUTICS, INC. (US) 2011-07-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224432-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 ADORA2A 227/4885ADORA1 1519/4885ADORA3 199/4885
US-20110230494-A1 HETEROARYL COMPOUNDS AND USES THEREOF ABCG2, CYP3A43, CYP3A5 ADORA2A 227/4885ADORA1 1519/4885ADORA3 199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.